Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: A comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAbs

Clinical Immunology

Volumn 157, Issue 1, 2015, Pages 91-101

  Gibbs, Ebrima ^a   Karim, Mohammad Ehsanul ^a   Oger, Joel ^a   Edan, Gilles ^b   Freedman, Mark S ^c   Hartung, Hans Peter ^d   Kappos, Ludwig ^e   Miller, David ^f   Montalbán, Xavier ^g   Pleimes, Dirk ^h   Pohl, Christoph ^i,j   Polman, Chris ^k   Sandbrink, Rupert ^d,i  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Clinique Neurologique   (France)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h BAYER CORPORATION   (United States)

ⁱ BAYER PHARMA AG   (Germany)

^j UNIVERSITY HOSPITAL BONN   (Germany)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Antibody dissociation rate; Biacore ; Immunogenicity; Interferon beta; Multiple sclerosis; Transient and sustainedneutralizing antibody

Indexed keywords

INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; BETA INTERFERON; PROTEIN BINDING;

ANTIBODY DISSOCIATION RATE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BIOSENSOR; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISSOCIATION; DRUG EFFICACY; HUMAN; MOLECULAR INTERACTION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SURFACE PLASMON RESONANCE; TECHNOLOGY; CLINICAL TRIAL; IMMUNOLOGY; IMMUNOTHERAPY; PATHOPHYSIOLOGY;

ANTIBODIES, NEUTRALIZING; HUMANS; IMMUNOTHERAPY; INTERFERON-BETA; MULTIPLE SCLEROSIS; PROTEIN BINDING;

EID: 84922553104     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.12.005     Document Type: Article

References (24)

1. Schellekens H. The immunogenicity of therapeutic proteins. Discov. Med. 2010 Jun, 9(49):560-564.
2. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 2002 Feb 14, 346(7):469-475.
3. Singh S.K., Cousens L.P., Alvarez D., Mahajan P.B. Determinants of immunogenic response to protein therapeutics. Biologicals 2012 Sep, 40(5):364-368.
4. Swanson S.J., Bussiere J. Immunogenicity assessment in non-clinical studies. Curr. Opin. Microbiol. 2012, 15(3):337-347. (6 //).
5. Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnology Annual Review 2008, vol. 14:191-202. Elsevier. M.R. El-Gewely (Ed.).
6. Goodin D.S. The use of interferon Beta and glatiramer acetate in multiple sclerosis. Semin. Neurol. 2013 Feb, 33(1):13-25.
7. Hecker M., Hartmann C., Kandulski O., Paap B.K., Koczan D., Thiesen H.J., et al. Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood. Mol. Neurobiol. 2013 May, 1.
8. Scagnolari C., Bellomi F., Turriziani O., Bagnato F., Tomassini V., Lavolpe V., et al. Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations. J. Interferon Cytokine Res. 2002 Feb, 22(2):207-213. (PubMed PMID: 11911803).
9. Bellomi F., Scagnolari C., Tomassini V., Gasperini C., Paolillo A., Pozzilli C., et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6years. J. Neurol. Sci. 2003 Nov 15, 215(1-2):3-8.
10. Hartung H.P., Kieseier B., Goodin D.S., Arnason B.G., Comi G., Cook S., et al. Variability in detection and quantification of interferon beta-1b-induced neutralizing antibodies. J. Neuroinflammation 2012, 9:129.
11. Gibbs E., Oger J. The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients. J. Neuroimmunol. 2007 Oct, 190(1-2):146-150.
12. Kappos L., Freedman M.S., Polman C.H., Edan G., Hartung H.P., Miller D.H., et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009 Nov, 8(11):987-997.
13. Hartung H.P., Freedman M.S., Polman C.H., Edan G., Kappos L., Miller D.H., et al. Interferon beta-1b-neutralizing antibodies 5years after clinically isolated syndrome. Neurology 2011 Aug 30, 77(9):835-843.
14. Farrell R.A., Marta M., Gaeguta A.J., Souslova V., Giovannoni G., Creeke P.I. Development of resistance to biologic therapies with reference to IFN-beta. Rheumatology 2012 Apr, 51(4):590-599.
15. Sorensen P.S. Neutralizing antibodies against interferon-beta. Ther. Adv. Neurol. Disord. 2008 Sep, 1(2):125-141.
16. Group TIMSSGatUoBCMMA. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996 Oct, 47(4):889-894.
17. Boz C., Oger J., Gibbs E., Grossberg S.E. Neurologists of the UBCMSC. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Mult. Scler. 2007 Nov, 13(9):1127-1137.
18. Jason-Moller L., Murphy M., Bruno J. Overview of Biacore™ systems and their applications. Current Protocols in Protein Science 2001, John Wiley & Sons, Inc.
19. Gibbs E., Oger J. A biosensor-based characterization of the affinity maturation of the immune response against interferon-beta and correlations with neutralizing antibodies in treated multiple sclerosis patients. J. Interf. Cytokine Res. 2008 Dec, 28(12):713-723.
20. Redlich P.N., Hoeprich P.D., Colby C.B., Grossberg S.E. Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping. Proc. Natl. Acad. Sci. U. S. A. 1991 May 1, 88(9):4040-4044.
21. Files J.G., Gray J.L., Do L.T., Foley W.P., Gabe J.D., Nestaas E., et al. A novel sensitive and selective bioassay for human type I interferons. J. Interferon Cytokine Res. 1998 Dec, 18(12):1019-1024.
22. Rice G.P., Paszner B., Oger J., Lesaux J., Paty D., Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999 Apr 12, 52(6):1277-1279.
23. Smyth P., Gibbs E., Tremlett H., Pachner A., Oger J. MxA induction can be regained after loss of neutralizing antibodies with continued Interferon-β treatment. Mult. Scler. 2004, 10(2):S252.
24. Goodin D.S., Hartung H.P., O'Connor P., Filippi M., Arnason B., Comi G., et al. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult. Scler. 2012 Feb, 18(2):181-195.